The words and actions of US President Donald Trump are rocking the pharmaceutical industry. On May 5, he said he…
HOME > REGULATORY
REGULATORY
- Applicants Objected to Proposed NHI Prices for 16 APIs in April 2010-May 2013; Revisions Made for 5 APIs
August 26, 2013
- First Committee Recommends Approval of Takeda’s Anti-Obesity Drug OBLEAN, Other Products
August 26, 2013
- Bill Payer and Healthcare Reps Support MHLW Proposal to Reduce NHI Prices; Industry Reps Want a Hold on a Decision
August 26, 2013
- Pharma Industry to Give Opinions at CSIMC Subcommittee in Sept., Stand against Health Ministry’s Plan to Cut Drug Prices
August 26, 2013
- CSIMC Sets No Prescription Limit for Irtra Combination Tablets
August 23, 2013
- CSIMC Approves Listing of 12 APIs, Parjeta Gets 5% Premium for Usefulness
August 23, 2013
- MHLW Proposes Plan to Downwardly Revise NHI Prices of Combination Drugs and Drugs Obtained as a Result of Optical Resolution of Racemic Bodies
August 23, 2013
- “Zero Risk” of Tumorigenicity from Products Using iPS Cells Cannot Be Guaranteed at Present: PMDA’s Science Board
August 23, 2013
- Health Ministry Notifies Prefectures of Approval for Xolair, Other Products
August 22, 2013
- MHLW to Draft New Guidance on Companion Diagnostics by End of 2013: Director Sato of ELD
August 20, 2013
- Takeda’s OBLEAN Joins Aug. 22 Review List of PAFSC 1st Committee
August 19, 2013
- 30-Plus Companies Gain Approval for Livalo, Valtrex Generics towards December Listing
August 16, 2013
- Case of Chagas Disease Confirmed through Blood Donation Raises Concern Over Secondary Infection
August 16, 2013
- 3 Ex-Officials of MHLW, NHO Affiliated with Novartis in 2010, Govt Says
August 15, 2013
- PMDA Meets All Targets for FY2012 with Exception of Time Spent by Applicants for Non-Priority Products
August 15, 2013
- Can Japan Become the Global Leader in Drug Discovery? New Vision for Pharmaceutical Industry Drops Company Categories Included in the Previous One
August 15, 2013
- PAFSC 2nd Committee to Review GSK’s Combination Asthma Drug on Aug. 26
August 14, 2013
- MHLW Compiles Report on Expert Council on Future Cancer Research
August 14, 2013
- EAD Director Visits 5 Hospital HQ to Urge Early Price Settlements, Greeted with Mixed Enthusiasm
August 13, 2013
- 41,254 ADR Reports Received from Marketing Authorization Holders in FY2012: MHLW
August 13, 2013
ページ
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…